On Apr. 30, 2020, Evotec announced that its Seattle-based subsidiary Just – Evotec Biologics had entered into a partnership with Ology Bioservices for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.

This work falls under a contract awarded to Ology Bio by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention of infections with SARS-CoV-2.